| Barnesville Vision Center Llc | |
| 177 E Main St, Barnesville, Ohio 43713 | |
| (740) 425-7000 |
| Name | Barnesville Vision Center Llc |
|---|---|
| Organization Name | Barnesville Vision Center, Llc |
| Location | 177 E Main St, Barnesville, Ohio 43713 |
| Type | Supplier |
| Phone | (740) 425-7000 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
CitiusTech announced today that BI-Clinical Framework 10.3 is 2011/2012 compliant and was certified as an EHR Module on May 12, 2011 by the Certification Commission for Health Information Technology, an ONC-ATCB, in accordance with the applicable Eligible Hospital certification criteria adopted by the Secretary of Health and Human Services.
Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.
NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma's external trigeminal nerve stimulation (eTNS) System.
The Association for Computing Machinery (ACM) awarded its first ACM Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research to a multi-institution research team that included the U.S. Department of Energy's (DOE) Argonne National Laboratory.
› Verified 8 days ago
News Archive
CitiusTech announced today that BI-Clinical Framework 10.3 is 2011/2012 compliant and was certified as an EHR Module on May 12, 2011 by the Certification Commission for Health Information Technology, an ONC-ATCB, in accordance with the applicable Eligible Hospital certification criteria adopted by the Secretary of Health and Human Services.
Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.
NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma's external trigeminal nerve stimulation (eTNS) System.
The Association for Computing Machinery (ACM) awarded its first ACM Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research to a multi-institution research team that included the U.S. Department of Energy's (DOE) Argonne National Laboratory.
› Verified 8 days ago
Health Care Solutions Type: Durable Medical Equipment & Medical Supplies Supplier Location: 114 Mill St, Barnesville, Ohio 43713 Phone: (740) 425-9420 | |
Cheffy Drug Llc Type: Community/Retail Pharmacy Location: 148 E Main St, Barnesville, Ohio 43713 Phone: (740) 425-1582 | |
Walgreens #17826 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 901 E Main St, Barnesville, Ohio 43713 Phone: (740) 425-1003 | |
Barnesville Vision Center Llc Type: Medicare Supplier Location: 177 E Main St, Barnesville, Ohio 43713 Phone: (740) 425-7000 |